NCT00522990View on ClinicalTrials.gov

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid LeukemiaMyelodysplastic SyndromesMyelofibrosis
Interventions
DRUG

AT9283

Three weekly intravenous administration of AT9283

Trial Locations (2)

35294

University of Alabama at Birmingham, Birmingham

77030

The University of Texas, MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Astex Pharmaceuticals, Inc.

INDUSTRY